Category1 Category2 Category3

The Japanese pharmaceutical offers to buy Ariad Pharmaceuticals for $5.2 billion, about 75 percent above the price where the biotechâ€™s shares were trading.

ID:http://www.nytimes.com/2017/01/09/business/dealbook/takedas-bid-for-cancer-drug-maker-looks-expensive.html_0